- Home
- PWM vs FGEN Comparison
PWM vs FGEN Comparison
Compare PWM & FGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PWM
- FGEN
- Stock Information
- Founded
- PWM 2018
- FGEN 1993
- Country
- PWM Hong Kong
- FGEN United States
- Employees
- PWM N/A
- FGEN N/A
- Industry
- PWM
- FGEN Biotechnology: Pharmaceutical Preparations
- Sector
- PWM
- FGEN Health Care
- Exchange
- PWM Nasdaq
- FGEN Nasdaq
- Market Cap
- PWM 34.6M
- FGEN 34.5M
- IPO Year
- PWM 2023
- FGEN 2014
- Fundamental
- Price
- PWM $0.70
- FGEN $0.71
- Analyst Decision
- PWM
- FGEN Strong Buy
- Analyst Count
- PWM 0
- FGEN 1
- Target Price
- PWM N/A
- FGEN $10.00
- AVG Volume (30 Days)
- PWM 1.3M
- FGEN 7.2M
- Earning Date
- PWM 02-13-2025
- FGEN 03-04-2025
- Dividend Yield
- PWM N/A
- FGEN N/A
- EPS Growth
- PWM N/A
- FGEN N/A
- EPS
- PWM N/A
- FGEN N/A
- Revenue
- PWM $639,912.00
- FGEN $180,015,000.00
- Revenue This Year
- PWM N/A
- FGEN $21.91
- Revenue Next Year
- PWM N/A
- FGEN N/A
- P/E Ratio
- PWM N/A
- FGEN N/A
- Revenue Growth
- PWM N/A
- FGEN 16.15
- 52 Week Low
- PWM $0.45
- FGEN $0.18
- 52 Week High
- PWM $2.70
- FGEN $2.80
- Technical
- Relative Strength Index (RSI)
- PWM 36.58
- FGEN 65.95
- Support Level
- PWM $0.50
- FGEN $0.54
- Resistance Level
- PWM $1.27
- FGEN $0.88
- Average True Range (ATR)
- PWM 0.35
- FGEN 0.07
- MACD
- PWM -0.07
- FGEN 0.02
- Stochastic Oscillator
- PWM 11.07
- FGEN 59.79
About PWM Prestige Wealth Inc.
Prestige Wealth Inc is engaged in providing private wealth management services and asset management to high-net-worth and ultra-high-net-worth individuals and enterprises through its subsidiaries.
About FGEN FibroGen Inc
FibroGen Inc is a biotechnology company focused on discovering, developing, and commercializing novel therapeutics to treat serious cancer biology and anemia. The Company operates in one reportable segment: the development and commercialization of novel therapeutics to treat serious unmet medical needs. The company generates the vast majority of its revenue in Europe, followed by Japan. Virtually all of FibroGen's revenue to date has been generated from its collaboration agreements. FibroGen seeks partners with research, development, and marketing capabilities and other resources that strengthen the company's ability to advance product candidates.